Detalhe da pesquisa
1.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38713888
2.
Biological relevance of alternative splicing in hematologic malignancies.
Mol Med
; 30(1): 62, 2024 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38760666
3.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36642080
4.
Molnupiravir is effective in patients with haematological malignancies.
Int J Cancer
; 153(6): 1251-1256, 2023 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36691818
5.
Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
Int J Cancer
; 152(4): 705-712, 2023 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35830214
6.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Br J Haematol
; 203(5): 792-802, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37691005
7.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Blood
; 137(10): 1365-1376, 2021 03 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32992344
8.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35810754
9.
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
Blood
; 130(14): 1628-1638, 2017 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28830887
10.
Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients.
Postepy Dermatol Alergol
; 36(2): 167-172, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-31320849
11.
Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells.
Haematologica
; 103(11): 1843-1852, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30002127
12.
Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis.
Postepy Dermatol Alergol
; 35(4): 344-350, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-30206445
13.
Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
Ann Hematol
; 96(1): 33-50, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27730344
14.
Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients.
Mediators Inflamm
; 2017: 5385102, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-29180838
15.
Specific cytotoxic T-cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells.
Br J Haematol
; 174(4): 582-90, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27097566
16.
PD1/PD1L pathway, HLA-G and T regulatory cells as new markers of immunosuppression in cancers.
Postepy Hig Med Dosw (Online)
; 70(0): 1044-1058, 2016 Oct 04.
Artigo
Inglês
| MEDLINE | ID: mdl-27708209
17.
Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia.
Acta Haematol
; 134(4): 255-62, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26159545
18.
Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance.
Eur J Haematol
; 92(2): 91-101, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24138550
19.
T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
Cancers (Basel)
; 16(8)2024 Apr 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38672662
20.
High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation.
Cells
; 13(8)2024 Apr 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38667336